Mymetics Corp. operates as a vaccine company. The firm focuses on the research and development of next generation vaccines for infectious and life disabling diseases. It has several vaccine candidates in pipeline: HIV-1/AIDS and Covid-19. Its vaccines for infectious diseases are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense in combination with humoral and cellular immune responses as a second-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. The company was founded in July 1994 and is headquartered in Epalinges, Switzerland.